Fannin Partners LLC

Houston, TX

UEI
DAHAYJEBV8K1
CAGE
7A2S4
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
Corporate family
SAM.gov registration date
Physical address
3900 Essex Ln #575, Houston, TX 77027, USA
Website
fannininnovation.com
Founded
2005
Employees
11-50
Industry
  1. Financials
  2. Diversified Financials
  3. Capital Markets
  4. Diversified Capital Markets
SIC code
67 Holding & Other Investment Offices
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Fannin Partners LLC's 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Development of a novel IL1RAP-directed drug conjugate for ewing sarcoma therapy. Grant · HT9425261E378 Defense Health Agency $139,896
Developing SCG3 raptamers as a novel targeted therapy for wet AMD - age-related macular degeneration (AMD) is a… Grant · R43EY037173 National Eye Institute $600,032
Development of a novel selective PDE4 inhibitor for the treatment of multiple sclerosis Grant · HT94252410819 Defense Health Agency $246,443
Investigation of a novel PDE4B inhibitor for stimulant use disorder - project summary fannin partners is developing a… Grant · R43DA060646 National Institute on Drug Abuse $320,000
Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and… Grant · R43FD007809 FDA Office of Acquisition and Grant Services $199,972

About Fannin Partners LLC

Written by GovTribe AI ·

Fannin Partners LLC is a Houston-based biomedical research and innovation company registered in the System for Award Management (SAM) since December 2014. The organization operates as a for-profit corporate entity focused on developing advanced therapeutic technologies and medical innovations across multiple healthcare domains. The company appears to leverage a proprietary platform for developing specialized molecular technologies, with a particular emphasis on aptamer-based research and therapeutic development targeting complex medical conditions.

Through its federal grant awards, Fannin Partners LLC has secured multiple project grants from prestigious federal agencies including the National Eye Institute, Defense Health Agency, National Institute on Drug Abuse, National Cancer Institute, Office of the Commissioner, and Office of the Director. Their grant-funded research spans diverse medical areas such as age-related macular degeneration, multiple sclerosis treatment, stimulant use disorder management, heart failure diagnostics, biomarker discovery, and cancer therapeutics. Specific projects include developing novel therapies like SCG3 raptamers for wet AMD, a PDE4 inhibitor for multiple sclerosis, an IL-7R antibody for treating T-cell leukemia, and an aptamer-based antivenom for snake bite envenomation. The company collaborates with research institutions like Baylor College of Medicine and has a sub-award relationship enabling senior research personnel to contribute to consortium-based medical device and therapeutic development initiatives.

Quick answers

What is Fannin Partners LLC's UEI?

Fannin Partners LLC's Unique Entity ID (UEI) in SAM.gov is DAHAYJEBV8K1.

What is Fannin Partners LLC's CAGE code?

Fannin Partners LLC's CAGE code is 7A2S4.

What is Fannin Partners LLC's primary NAICS code?

Fannin Partners LLC's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).

Where is Fannin Partners LLC located?

Fannin Partners LLC's physical address in SAM.gov is 3900 Essex Ln #575, Houston, TX 77027, USA.

Is Fannin Partners LLC registered in SAM.gov?

Yes. Fannin Partners LLC's SAM.gov registration is active through March 30, 2027.

What is Fannin Partners LLC's most recent federal award?

Fannin Partners LLC's most recent federal grant award is Development of a novel IL1RAP-directed drug conjugate for ewing sarcoma therapy (HT9425261E378), from Defense Health Agency, on July 15, 2026.

On GovTribe

See Fannin Partners LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login